期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

上皮-间质转化与肿瘤耐药性的研究进展 被引量：10

Epithelial-mesenchymal transition and drug resistance of tumors
下载PDF
导出
摘要 上皮-间质转化(EMT)是上皮细胞表型向间质细胞表型转变的过程,在肿瘤发生及其演变中发挥着重要的作用。近期研究表明,EMT在多种肿瘤的化疗耐药中发挥重要作用,而化疗药物也能增强肿瘤的恶性程度包括诱导EMT表型的产生。本文结合国内外最新报道,对EMT与肿瘤耐药关系的研究进展进行综述。 Differentiated epithelial cells could be transformed into mesenchymal cells through the epithelial-mesenchymal transi-tion （EMT）, which is important for tumorigenesis and metastasis. Recent studies suggest that EMT is closely correlated to the resistance to chemotherapy of tumors. This chemoresistance could enhance tumor malignancy, which includes the induction of the EMT pheno-type. The paper reviews the research progress on EMT and its association with drug resistance of tumors.
作者 袁玲 王朝霞
机构地区 南京医科大学第一临床医学院临床医学系 南京医科大学第二附属医院肿瘤科
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2013年第17期1068-1071,共4页 Chinese Journal of Clinical Oncology
基金 国家自然科学基金项目(编号:30973477 81272601) 江苏省自然科学基金项目(编号:BK2010590) 江苏省医学重点人才计划(编号:RC2011080)资助~~
关键词 上皮-间质转化 肿瘤 耐药性 epithelial-mesenchymal transition, tumor, drug resistance
分类号 R730.2 [医药卫生—肿瘤]
  • 相关文献

参考文献25

  • 1Yang J, Weinberg RA. Epithelial-mesenchymal transition:at the crossroads of development and tumor metastasis[J]. Dev Cell, 2008, 14(6):818-829.
  • 2陈杰,钱桂生,黄桂君.肺癌多药耐药性机制研究进展[J].中国癌症杂志,2002,12(3):273-276. 被引量：15
  • 3Shintani Y, Okimura A, Sato K, et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small ceil lung cancer[J]. Ann Thorac Surg, 2011, 92(5): 1794-1804.
  • 4Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer[J]. Cancer Res, 2009, 69(14) :5820-5828.
  • 5Foroni C, Broggini M, Generali D, et al. Epithelial-mesenchymal transition and breast cancer: Role, molecular mechanisms and clini- cal impact[J]. Cancer Treat Rev, 2012, 38(6):689-697.
  • 6Haslehurst AM, Koti M, Dharsee M, et al. EMT transcription fac- tors snail and slug directly contribute to cisplatin resistance in ovari- an cancer[J]. BMC Cancer, 2012, 12:91.
  • 7Rho JK, Choi YJ, Lee JK, et al. Epithelial to mesenchymal transi- tion derived from repeated exposure to gefitinib determines the sen- sitivity to EGFR inhibitors in A549,a non--small cell lung cancer cell line[J]. Lung Cancer, 2009, 63 (2):219-226.
  • 8Xie M, Zhang L, He CS, et al. Activation of Notch-1 enhances epi thelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells[J]. Cell Biochem, 2012, 113 (5):1501-1513.
  • 9Sakai A, Kasahara K, Ohmori T, et al. Mesenchymal-dpithelial transition factor increases the sensitivity of gefitiifib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity[J].J Thorac Oncol, 2012, 7(9):1337-1344.
  • 10Roselli M, Fernando RI, Guadagni F, et al. Brachyury, a driver of the Epithelial-Mesenchymal Transition, Is Overexpressed in Hu- man Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer[J]. Clin Cancer Res, 2012, 18(14):3868-3879.

二级参考文献48

  • 1[12]Loe DW, Deeley RG, Cole SPC, et al. Biology of the multidrug resistance-associated protein [J]. Eur J Cancer,1996,32A(6):945-957.
  • 2[13]Campling BG, Young LC, Baer KA, et al. Expression of the MRP and MDR1 multidrug resistance genes in small-cell lung cancer [J]. Clin Cancer Res,1997,3(1):115-122.
  • 3[14]Narasaki F, Matsuo I, Ikuno N, et al. Multidrug resistance-associated protein (MRP) gene expression in human lung cancer [J]. Anticancer Res,1996,16(4A):2079-2082.
  • 4[15]Wright SR, Boag AH, Valdimarsson G, et al. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung [J]. Clin Cancer Res,1998,4(9): 2279-2289.
  • 5[16]Oshika Y, Nakamura M, Tokunaga T, et al. Multidrug resistance-associated protein and mutant p53 protein expression in non-small-cell lung cancer [J]. Mod Pathol,1998,11(11):1059-1063.
  • 6[17]Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a Mr 110 000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance [J]. Cancer Res,1993,53(7):1475-1479.
  • 7[18]Scheffer GL,Schroeijers AB, Izquierdo MA, et al. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer[J]. Curr Opin Oncol,2000,12(6): 550-556.
  • 8[19]Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribution of the multidrug resistance related vault lung resistance protein in normal human tissues and tumors [J]. Am J Pathol,1996,148(3):877- 887.
  • 9[20]Izquierdo MA, Scheffer GL, Flens MJ, et al. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs [J]. Cytotechnology,1996,19(3):191-197.
  • 10[21]Dingemans AM, van Ark Otte J, van der Valk P et al. Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues [J]. Ann Oncol,1996,7(6): 625-630.

共引文献33

同被引文献133

引证文献10

二级引证文献21

中国肿瘤临床
2013年 第17期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部